Design RNA therapeutics with explainable AI.
Your partner for precise and exceptional designs.
Leading in short oligonucleotide innovation and design.
Precision RNA therapeutics with ASOs, siRNAs, and antimiRs.
We’re redefining the potential of RNA therapeutics through our specialized workflow with ASOs, siRNAs, and antimiRs.
This focus ensures our therapeutics have high activity and exhibit minimal off-target effects, heralding a new era of precision medicine.
Abzu’s measurable impact in RNA therapeutic design.
Where proven results speak louder than promises, Abzu stands apart.
Abzu is your partner in RNA therapeutics design.
A cycle of innovation and optimization — to RNA therapeutics realization.
The latest in research, perspective, and events.
Your next RNA therapeutics design insight starts here.
Since a key challenge in designing oligonucleotides is the potential for toxicity, especially at high doses, using machine learning to mitigate this challenge would be an enormous benefit to oligonucleotide medicines.
RNA Leaders Europe is the #1 event focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids & RNA targets.
Less data, more discovery.
Make the most out of every piece of information.
Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.
Let's unlock the future of RNA therapeutics together.
But first: Tell us about your scientific and business objectives.
Let’s have a conversation about your targets, therapies, and goals. If you want to transcend insufficient analytics and black-box AI, then please complete the form below — we look forward to chatting!